TheraP: A Randomised Phase 2 Trial of 177Lu-PSMA617 Theranostic Versus Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer (ANZUP Protocol 1603)
Phase of Trial: Phase II
Latest Information Update: 08 Feb 2018
At a glance
- Drugs PSMA 617 (Primary) ; Cabazitaxel
- Indications Prostate cancer
- Focus Registrational; Therapeutic Use
- Acronyms TheraP
- 30 Jan 2018 Status changed from not yet recruiting to recruiting.
- 29 Nov 2017 Status changed from planning to not yet recruiting.
- 10 Nov 2017 New trial record